SAFit2 is a highly effective and selective fk506 binding protein 51(FKBP51) inhibitor (Ki: 6 nM). SAFit2 can enhance AKT2-AS160 binding and participate in the downstream response of glucocorticoid release in vivo, and is a candidate compound for the treatment of obesity, chronic pain, depression and anxiety.

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

Dimiracetam (NT-11624) is an orally active anti-neuropathy compound that inhibits hypersensitivity and neurological alterations and may be used in the study of cognitive disorders, depression and neuropathic pain.

CP 316311 is a specific CRF1 receptor antagonist with potential antidepressant activity and may be used in the study of depression.

(S)-3-Hydroxybutanoic acid (L-(+)-3-Hydroxybutyric acid) is a normal human metabolite that has been found elevated in geriatric patients remitting from depression. (S)-3-Hydroxybutanoic acid is synthesized in the liver from acetyl-CoA in humans, and can be used as an energy source by the brain when blood glucose is low.

L-Threonine (threonine) is an essential amino acid in humans，an important amino acid for the nervous system,L-Threonine also plays an important role in porphyrin and fat metabolism and prevents fat buildup in the liver. Useful with intestinal disorders and indigestion, threonine has also been used to alleviate anxiety and mild depression.

ELB-139 is a GABAA receptor agonist that can be used to study depression and epilepsy.

Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.

[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methanamine is a piperazine derivative that is a partial agonist at serotonin and dopamine receptors, making it a candidate for the treatment of psychiatric disorders such as depression and schizophrenia.

Enciprazine (D-3112) has anxiolytic activity with high affinity for 5-HT1A receptor and ADRA1, which can be used for the treatment of anxiety disorders and can be used to study depression.

(S)-(+)-Niguldipine hydrochloride is a selective α1A-AR antagonist used in the study of depression and epilepsy.

JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic

Tampramine is a selective norepinephrine reuptake inhibitor that shows a low affinity for adrenergic, histaminergic and muscarinic receptors. Tampramine is a candidate compound for the treatment of forced swimming test (FST) depression.

PDE IV-IN-1 is a potent phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory activity for the treatment of asthma, chronic obstructive pulmonary disease and other inflammatory diseases, and is a potential compound for the study of depression.

2-Chlorophenylboronic acid is a monohalogenated phenylboronic acid, which is an important pharmaceutical intermediate and is widely used in the synthesis of new drugs.2-Chlorophenylboronic acid has an inhibitory effect on fatty acid amidase with a Ki value of 0.01-1 µM, and is used in the study of depression, glaucoma, neuropathic pain, anxiety, migraine, I diabetes and gastritis. , migraine, type I diabetes and gastritis.

Fengabine (SL-79229) is a GABA receptor agonist with antidepressant activity and is used to treat depression.

Debrisoquin hydriodide (1,2,3,4-tetrahydroisoquinoline-2-carboximidamide hydroiodide) has antioxidant, anti-inflammatory and neuroprotective properties. It has also been found to modulate the activity of certain neurotransmitters, including dopamine and serotonin, making it a promising candidate for the treatment of neurological disorders such as Parkinson's disease and depression.

Desoxypeganine (Deoxypeganine) is an inhibitor of cholinesterase. It acting preferentially on butyrylcholinesterase, and as a selective inhibitor of monoamine oxidase A but not monoamine oxidase B.Desoxypeganine is being developed for its potential utility in the pharmacological treatment of alcohol abuse to reduce craving and depression in alcohol abusers, and might also be useful as a smoking cessation aid.

Viloxazine (Viloxazin) (Viloxazin) is a dual-action compound that functions as a norepinephrine reuptake inhibitor and exhibits potent agonistic activity towards 5-HT 2C receptors while acting as an antagonist for 5-HT 2B receptors, with respective potency values of EC 50 = 32 μM and IC 50 = 27 μM. Its primary mechanism of action involves the modulation of serotonergic and noradrenergic pathways. Viloxazine is commonly employed in depression research [1] [2].

Pipoxazole (COR-32-24) is an adrenergic receptor agonist that can be used to study depression.

3-(2-phenylethynyl)pyridine is a pyridine derivative that is a ligand for a variety of receptors in the human body, including dopamine D2 receptors, sigma-1 receptors, and 5-HT6 receptors. It has been studied for the treatment of various neurological disorders, including schizophrenia, depression and Alzheimer's disease.

E6801 is a novel selective 5-HT6 receptor agonist with a wide range of biological activities.E6801 can be used in the study of dementia, Parkinson's disease, depression, obesity epilepsy, anxiety, and many other diseases.

Bazinaprine is a selective, reversible monoamine oxidase inhibitor (MAOI) that is a candidate compound for the treatment of depression. Bazinaprine showed strong inhibitory effect on type A monoamine oxidase and weak inhibitory effect on type b monoamine oxidase. Bazinaprine is reversible in vivo, but not in vitro.

Euxanthone (1,7-Dihydroxyxanthone), an xanthone derivative extracted from the roots of Polygala tenuifolia Willd, has antitumour, neuroprotective and vasorelaxant activities, and attenuates Aβ1-42-induced oxidative stress and apoptosis by inducing autophagy.SB-674042 is used for the treatment of depression.SB-674042 is used for the treatment of depression.SB-674043 is used for the treatment of depression.SB-674044 is used for the treatment of depression.SB-674045 is used for the treatment of depression. 2A (BU-1) cell differentiation.

Femoxetine hydrochloride is a selective 5-hydroxytryptamine reuptake inhibitor used in the study of migraine, depression and eating disorders.

pep2-AVKI acetate(1315378-69-8 free base) An inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to proteins that interact with C-kinase (PICK1). Does not affect GluA2 binding to GRIP or ABP, nor does it increase AMPA current amplitude or affect long-term depression (LTD).

Raxatrigine (CNV 1014802) has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

Acetophenazine is an anxiolytic compound that is used in the study of depression.

Nitroxazepine (CIBA 2330Go) is a serotonin-norepinephrine reuptake inhibitor, and treatment depression. Nitroxazepine is a tricyclic antidepressant (TCA) for the research of depression

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Adatanserin (WY 50324) is a mixed 5-HT1A receptor partial agonist and a 5-HT2A and 5-HT2C receptor antagonist with potential neuroprotective activity for the study of coke oven and depression.

Antidepressant agent 5 is a 7-substituted tetrahydroisoquinoline derivative with antidepressant activity.Antidepressant agent 5 acts similarly to magnoflorine in the study of depression and can be used for the prevention and treatment of depressive disorders.

6-Chloromelatonin is a potent melatonin receptor agonist, a 5-methoxyindole compound that competes for the same presynaptic melatonin receptor sites in the rabbit retina and inhibits the calcium-dependent release of [3H]dopamine with a higher metabolic stability than melatonin. Chloromelatonin competes for [3H]melatonin binding to MT2 receptors (pKi=9.77) and may be used to study insomnia and sleep disorders associated with depression.

Repinotan (BAY x 3702 free base) is an orally active and selective 5-HT1A receptor agonist that crosses the blood-brain barrier (BBB), has neuroprotective activity, antagonizes morphine-induced depression of ventilation in anesthetized rats, and can be used in studies of acute ischemic stroke and traumatic brain injury.

Osemozotan HCl (Osemozotan hydrochloride) is a novel and selective 5-HT1A receptor agonist that reduces methamphetamine-induced c-Fos expression in the medial prefrontal cortex and striatum.Osemozotan HCl is used in the study of mechanical abnormalities of pain and depression.

Mianserin, an H1 receptor reverse agonist, is a psychoactive compound in the tetracyclic antidepressant (TeCA) treatment family. Mianserin has antidepressant, antianxiety, antiemetic, hypotrophic, hypnotic and antihistamine effects, and can be used as a combination of norepinephrine and specific serotonin to treat depression.

Adatanserin hydrochloride (WY50324 hydrochloride) is a novel 5-HT(1A)/5-HT(2) receptor ligand with potential neuroprotective effects and inhibition of ischemic efflux of endogenous amino acids, which can be used in the study of depression and anxiety disorders.

Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.

BW-1370U87 is a reversible competitive monoamine oxidase-A inhibitor for the study of depression and other CNS disorders.

3-hydroxy-3-phenylpentanamide is a chiral compound belonging to the class of beta-hydroxyamides. In neurology, it has been shown to have neuroprotective effects against ischemic brain injury and cerebral hemorrhage. In psychiatry, it has been studied as a potential treatment for anxiety, depression and addiction. In oncology, it has been shown to have antitumor activity by inducing apoptosis and inhibiting tumor growth.

napitane (A 75200) is a novel catecholamine uptake inhibitor with inhibitory effects on α-adrenergic receptors and potential antidepressant activity for the study of depression.

Delucemine Hydrochloride (Delucemine) is a polyamine NMDA receptor antagonist used in the study of neurological disorders such as depression and Alzheimer's disease.

CI 169369 is a selective 5-HT2 receptor antagonist used in the study of anxiety and depression.

Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide) is a serotonin-norepinephrine-dopamine reuptake inhibitor and an antagonist of 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptors, which can be used to treat depression and anxiety.

LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.

Oxaprotiline is an antidepressant compound. It is a norepinephrine reuptake inhibitor that blocks histamine H1 receptors. Oxaprotiline has been studied for its efficacy in treating hospitalized patients with depression, but it is not on the market.

SKF83959, a benzazepine analog, is a selective and potent partial agonist of the dopamine D1 receptor with Ki values of 1.18, 7.56, 920, and 399 nM for rat D1, D5, D2, and D3 receptors, respectively.SKF83959 is a potent variant modulator of the sigma (σ)-1 receptor, which ameliorates cognitive dysfunction for the study depression and Alzheimer's disease.

OPC-14523, a 5-HT1A receptor agonist, is used potentially for the treatment of depression and neuropathic pain.

JNJ-54175446 (JNJ-5446) is a CNS-permeable and selective P2X7 receptor antagonist that attenuates the release of IL-1β/IL-18 from microglia, and may be used in the study of depression.

Ampreloxetine hydrochloride (TD-9855 HCl) has anti-inflammatory activity and is a potential compound for the treatment of depression and Alzheimer's disease.